New hope for kids with tough cancers: testing a targeted drug
NCT ID NCT04925609
Summary
This study is testing a drug called brigatinib in children and young adults (ages 1 to under 26) with specific cancers that have a genetic change called ALK-positive. The cancers include anaplastic large cell lymphoma (ALCL), inflammatory myofibroblastic tumors (IMT), and other solid tumors that have come back or not responded to standard treatments. The first part of the study aims to find the safest and most effective dose. The second part will see how well the drug works at controlling these cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institut Gustave Roussy
RECRUITINGParis, 94805, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Princess Máxima Center for Pediatric Oncology
RECRUITINGUtrecht, Utrecht, 3584 CS, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.